lurasidone-hydrochloride and Metabolic-Diseases

This paper reviews the pharmacokinetic and safety profile of lurasidone from the perspective of clinical pharmacology and helps the clinician compare this drug with others from the same therapeutic class to aid in drug selection and use in specific situations.. We reviewed the literature using the keywords 'lurasidone,' 'schizophrenia' and 'clinical trials.' In our review, particular attention was paid to those articles that reviewed the pharmacokinetic characteristics of the drug and its efficacy and safety/tolerability based on data from registration trials.. Lurasidone may be more effective and/or better tolerated than other antipsychotics by some patients although there is currently no way to identify which patients will best respond to which antipsychotic medication. Data from clinical trials of lurasidone in schizophrenia suggest a lower likelihood of weight gain and metabolic problems in patients being treated with lurasidone versus olanzapine and quetiapine.

Topics: Animals; Antipsychotic Agents; Humans; Lurasidone Hydrochloride; Metabolic Diseases; Schizophrenia; Weight Gain

Patients with schizophrenia are at higher risk of cardiovascular morbidity and mortality than healthy individuals. This study was conducted to compare the effect of lurasidone and olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia.. The present study was a randomized open-label, parallel design, active-controlled clinical trial. After recruitment and randomization of 101 patients, a baseline assessment was done by PANSS, SOFAS, lipid profile, fasting blood glucose, HbA. There was a significant increase in fasting blood glucose (p < 0.001), HbA. Lurasidone showed a favourable effect on lipid profile and cardiovascular risk indices over olanzapine. However, long-term studies are needed to establish and generalize the findings.. ClinicalTrials.gov NCT03304457.

Topics: Adult; Antipsychotic Agents; Blood Glucose; Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Lipids; Lurasidone Hydrochloride; Male; Metabolic Diseases; Middle Aged; Olanzapine; Schizophrenia; Treatment Outcome; Young Adult